risk factors to predict post-cd19 car-t cell therapy outcomes in patients with lbcl
Published 1 year ago • 176 plays • Length 4:05Download video MP4
Download video MP3
Similar videos
-
2:26
clinical data for cd19-directed car t-cell products in all
-
3:18
evaluating dual-targeting cd19/22 car-t cells in patients with r/r all
-
3:07
the role of bridging and timing in car-t
-
1:16
the efficacy of car t-cell therapy in richter's transformation
-
1:59
efficacy and safety of cd19-targeted car t-cells for relapsed/refractory all
-
4:12
opportunities to improve car-t outcomes
-
1:21
anti-cd22 car t-cell therapy for all: trial update, utility for salvage and cd19 status
-
1:11
genomic testing can help identify patient risk factors and guide clinical decision-making
-
3:01
mechanisms of antigen escape following cd19-directed car-t therapy
-
3:06
repeat infusions of cd19 car-t
-
10:22
cd19 car-t in lymphoma patients in the uk
-
3:28
the use of anti-cd19 car-t therapy for richter’s transformation
-
1:40
overcoming antigen escape following cd19-directed car-t therapy
-
2:06
managing and treating crs, neurological toxicity and cytopenias associated with car-t therapy
-
4:49
hematopoietic recovery post-car-t
-
2:01
advances in cd22/cd19 car-t sequential therapy
-
1:43
the co-administration of bispecific antibodies and car t-cells in cll: an in vivo study
-
6:42
trial shows car t-cell therapy prolongs remission in paediatric relapsed or refractory all